DFC CEO Adam Boehler and Kodak CEO Jim Continenza (Kodak)

Covid-19 roundup: Cure­Vac beefs up its uni­corn IPO dreams as bil­lion­aire own­er takes this Covid-19 mR­NA play­er on a forced march to Nas­daq; Ko­dak's $765M deal is put on hold

When Cure­Vac ini­tial­ly jot­ted down $100 mil­lion for its IPO raise a cou­ple of weeks ago, it seemed small. The Ger­man mR­NA play­er, af­ter all, had jumped in­to a Covid-19 race that swelled the sails of Mod­er­na and BioN­Tech by tens of bil­lions. And af­ter rais­ing $640 mil­lion in a slate of deals, $100 mil­lion in a hot mar­ket like this seemed like a pit­tance in the big­ger scheme of things.

To­day, we got a look at a fig­ure that prob­a­bly comes clos­er to the game-chang­ing num­ber the top ex­ecs prob­a­bly have in mind. Sell­ing 15.3 mil­lion shares at the high end of their $14 to $16 range would net a $243 mil­lion boun­ty. Ma­jor­i­ty own­er Di­et­mar Hopp is putting in an­oth­er €100 mil­lion, bring­ing the to­tal to around $350 mil­lion. And what are the chances they want to do even bet­ter than that?

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.